Teva Pharmaceuticals Reports Third-Quarter Adjusted EPS
Valid market news retained in the public archive without immediate LiveCast distribution.
Related stories
Columbus McKinnon Raises Fiscal 2027 Guidance; Shares Rise More Than 15%
Columbus McKinnon raised its fiscal 2027 guidance, and its shares were up more than 15%.
M impact | EARNINGS | Nov 03, 2026, 07:30 PM UTC
Dana Raises 2026 Sales Guidance to About $7.8 Billion
Dana raised its sales forecast for 2026 to about $7.8 billion.
M impact | EARNINGS | Nov 03, 2026, 07:24 PM UTC
Weng Fine Art Cuts 2025 Net Profit to About EUR 4.7 Million
Weng Fine Art cut its 2025 net profit forecast to about EUR 4.7 million after accounting corrections.
M impact | EARNINGS | Nov 03, 2026, 07:10 PM UTC
Deckers Raises Fiscal 2027 EPS Guidance to $7.80-$7.95
Deckers said international sales rose 9% year over year to $644.7 million, while consolidated revenue grew 3.5%. The revised EPS outlook includes about 52 cents per share from IEEP
M impact | EARNINGS | Nov 03, 2026, 07:03 PM UTC
Jabil Raises Fiscal 2026 Guidance, Provides Fiscal 2027 Outlook
Jabil raised fiscal 2026 revenue guidance to $21 billion from $20.5 billion and adjusted EPS guidance to $11.55 from $11.30. For fiscal 2027, it projects revenue of $40 billion and
M impact | EARNINGS | Nov 03, 2026, 07:03 PM UTC
International Paper Sets FY2026 EBITDA Guidance at €730M–€780M
The company said its planned separation remains on schedule and expects its pan-European packaging platform to generate approximately €480 million in annualized savings by the end
M impact | EARNINGS | Nov 03, 2026, 07:03 PM UTC